ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: SA-PO0475

Juxtaglomerular Effects of SPAK Deficiency Enhance the Glomerular Filtration Rate

Session Information

Category: Fluid, Electrolytes, and Acid-Base Disorders

  • 1101 Fluid, Electrolyte, and Acid-Base Disorders: Basic

Authors

  • Mutig, Kerim, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation
  • Yilmaz, Duygu Elif, Charité-Universitätsmedizin Berlin, Berlin, Germany
  • Saritas, Turgay, University Hospital RWTH Aachen, Aachen, Germany
  • Demirci, Hasan, Charité-Universitätsmedizin Berlin, Berlin, Germany
  • Ferdaus, Mohammed Zubaerul, Vanderbilt University School of Medicine, Nashville, Tennessee, United States
  • McCormick, James A., Oregon Health and Science University, Portland, Oregon, United States
Background

Na+-K+-2Cl- cotransporter (NKCC2) of the thick ascending limb (TAL) and macula densa (MD) cells is critical to regulation of the glomerular filtration rate (GFR) via the tubulo-glomerular feedback (TGF). NKCC2 function relies on activating phosphorylation provided by two homologous STE20-related kinases, SPAK and OSR1, whereas a truncated, catalytically inactive, kidney-specific SPAK variant (KS-SPAK) limits this process via competitive binding to NKCC2. KS-SPAK is produced via alternative splicing or proteolytic cleavage by the aspartyl aminopeptidase (DNPEP). We hypothesized that SPAK isoforms participate in regulation of GFR via distinct effects on NKCC2 activity in TAL vs. MD cells.

Methods

The hypothesis was investigated in SPAK-deficient (SPAK-/-) vs. wild-type (WT) mice and in cultured TAL vs. MD cell using physiological, immunohistochemical, and biochemical methods.

Results

Compared to WT, SPAK-/- mice exhibited strongly enhanced baseline NKCC2 phosphorylation in TAL due to deletion of the dominant-negative KS-SPAK and disinhibition of OSR1. In contrast, MD cells of SPAK-/- mice showed no changes in NKCC2 phosphorylation suggesting the absence of KS-SPAK in this cell type. Indeed, analysis of SPAK isoforms in cultured MD vs. TAL cells revealed high expression of the full-length SPAK in MD cells, whereas TAL cells predominantly exhibited KS-SPAK. Accordingly, DNPEP expression was markedly stronger in TAL compared to MD cells. Juxtaglomerular expression of cyclooxygenase 2 and nitric oxide synthase 1 were increased in SPAK-/- mice likely reflecting a reduced NaCl delivery to MD and TGF inhibition. Baseline GFR was higher in SPAK-/- compared to WT mice as determined by transcutaneous measurement using FITS-Sinistrin.

Conclusion

Thus, deletion of KS-SPAK along TAL prior to MD may reduce the NaCl load at MD, whereas deletion of FL-SPAK in MD cells may interfere with their NaCl sensitivity; both effects would synergistically augment GFR. Stronger DNPEP expression in TAL vs. MD cells further explains their distinct SPAK isoform profiles and functional effects of SPAK deletion. Since pharmacological SPAK inhibition is emerging as a therapeutic option for management of hypertension, improved understanding of renal SPAK effects is mandatory.

Digital Object Identifier (DOI)